A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat
about
Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibitionDisseminated Intracranial Ewing's Sarcoma in an Adult: A Rare and Difficult Diagnosis.The class I-specific HDAC inhibitor MS-275 modulates the differentiation potential of mouse embryonic stem cells.Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models.Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas.EphB2 activation is required for ependymoma development as well as inhibits differentiation and promotes proliferation of the transformed cell.Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)Mutations in chromatin machinery and pediatric high-grade gliomaThe current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma.Promises and challenges of exhausting pediatric neural cancer stem cells.Emerging insights into the ependymoma epigenome.Targeting of histone deacetylases in brain tumors.Medulloblastoma and ependymoma cells display increased levels of 5-carboxylcytosine and elevated TET1 expression.Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristicsHD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.Study of stem cell marker nestin and its correlation with vascular endothelial growth factor and microvascular density in ependymomas.Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma.Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model.Translating preclinical hopes into clinical reality for children with ependymoma.Nestin expression identifies ependymoma patients with poor outcome.Put away your microscopes: the ependymoma molecular era has begun.The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells.Current treatment options for pediatric and adult patients with ependymoma.Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors.Effects of epidermal growth factor receptor blockade on ependymoma stem cells in vitro and in orthotopic mouse models.
P2860
Q28484418-8EBDF7C4-51BC-4551-AC02-72C6709332DCQ30464395-F2A1CE13-17C0-47E2-92B3-EAC018A4CC8AQ30551120-08000FAF-9F36-4782-A60A-8E7EB5D786ABQ30613404-A0D78E63-B4F5-439D-B948-4C178FBA6015Q33894470-F32174AE-414D-444C-AB97-3DD6C631A121Q34552042-E66EA801-EBD3-4D80-A31F-157055F3A738Q35210469-E132441B-5141-45E9-9EA8-C381608240A9Q35246513-281AE1C4-CA0E-4D0D-AA25-0E6512C764FEQ36438027-20BC1D32-318C-4E3E-A830-96F81CC65CB3Q36716785-5B204FCD-07B0-4699-87FD-0BF1316198EEQ37553466-BAA9CB72-6F95-4665-AC00-B07C26F12905Q37641698-7A59484D-DBA3-4D5C-940B-F9305CFF81C6Q37995024-DB381D82-F1D3-46B5-8B43-D9A73A0A0C25Q38083798-31D7F0F1-9C21-440D-83BC-86C3CBC87DAEQ38233117-EB5507E6-555A-418D-A5D9-987AF0018220Q38715300-15D06076-DF29-4211-A2FF-DB27796286EEQ39120248-F86698AC-80FA-488E-91D6-02CF679096A1Q39262034-49B92145-8E2B-4933-901C-1A61FEB2B1F3Q39316156-405A9096-DC39-477F-BE2D-1354CD3458F7Q41109977-B661FE7B-3C11-408F-B5CE-EFE97E6CC931Q41344917-01CD81EB-55D1-4213-BA69-DE760D4FA004Q43187373-C23E754A-53DD-4E0A-B6CB-D7C00200A36CQ43662312-B7EE08F2-881E-43D0-9FA8-54416EAF9990Q47958629-C6764F82-C645-4CA8-8DF4-7BA34CF9AB67Q48117089-99FF2737-1A80-41CD-99F4-3C5A21845C31Q48439500-76801D42-5A70-4839-9DA2-C60DD08F1584Q52148322-52A5CA60-EE51-41EA-9387-3579E33BC4F5Q54336810-43A3D32F-F1C5-4927-BA7F-3167B7607DB5
P2860
A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
A novel human high-risk ependy ...... acetylase inhibitor Vorinostat
@en
A novel human high-risk ependy ...... cetylase inhibitor Vorinostat.
@nl
type
label
A novel human high-risk ependy ...... acetylase inhibitor Vorinostat
@en
A novel human high-risk ependy ...... cetylase inhibitor Vorinostat.
@nl
prefLabel
A novel human high-risk ependy ...... acetylase inhibitor Vorinostat
@en
A novel human high-risk ependy ...... cetylase inhibitor Vorinostat.
@nl
P2093
P2860
P50
P1476
A novel human high-risk ependy ...... acetylase inhibitor Vorinostat
@en
P2093
Andreas E Kulozik
Andrey Korshunov
Axel Benner
Hans-Georg Kopp
Hedwig E Deubzer
Hendrik Witt
Hermann-Josef Gröne
Manfred Jugold
Marco Lodrini
P2860
P2888
P304
P356
10.1007/S00401-011-0866-3
P577
2011-08-24T00:00:00Z